Bibliografisk note

Funding Information:
We are grateful to all study participants across multiple nephrology centers worldwide for their contributions to this manuscript. This work was supported by the following institutions, grants and funding agencies: Columbia University, Columbia Glomerular Center, IGA Nephropathy Foundation of America and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) grants R01-DK105124 (to K.K., J. Novak, B.A.J.), RC2-DK116690 (to K.K.) and R01-DK082753 (to A.G.G., J. Novak, K.K., F.S., B.A.J., R.J.W.). Additional support was provided by R01LM013061 (to K.K.), U01HG008680 (to K.K.), U01AI152960 (to K.K.), R01-DK078244 (to J. Novak, B.A.J.), R01-AI149431 (to J. Novak, B.A.J.), National Science Foundation of China (82022010 to X.-J.Z.; 82070733 to H.Z.), Beijing Natural Science Foundation (Z190023 to X.-J.Z.), Deutsche Forschungsgemeinschaft (DFG) Project-ID 192904750—CRC 992 Medical Epigenetics (to A. Köttgen, P. Schlosser), DFG Project-ID 431984000—CRC 1453 (to A. Köttgen) and EQUIP Program for Medical Scientists, Faculty of Medicine, University of Freiburg (to P. Schlosser). J.B.H., S.P., L.K. and M.W. were supported by R01HG010730, U01AI130830, R01NS099068, R01AI024717, R01AR073228, U01AI150748, R01AI148276, P01AI150585 and the US Department of Veterans Affairs Merit Award I01-BX001834 to J.B.H. D.P.G. was supported by the St Peter’s Trust for Kidney, Bladder and Prostate Research. The UK cohort data were generated as a result of a grant from Kidney Research UK and the Medical Research Council (to J. Barratt and D.P.G.). The German STOP-IgAN study was supported by the DFG (German Research Foundation)—CRU 5011—Project-ID 445703531 (to J.F., T.R.). The GCKD study was funded by grants from the German Ministry of Education and Research (BMBF, 01ER0804) and the KfH Foundation for Preventive Medicine. Unregistered grants to support the study were provided by Bayer, Fresenius Medical Care and Amgen. Genotyping was supported by Bayer Pharma AG. The recruitment of Polish cases with IgAN was sponsored by the Polish Kidney Genetics Network (POLYGENES), a collaborative effort between Columbia University and Poznań University of Medical Sciences, Poland. The recruitment of Czech patients with IgAN was supported by the research project of General University Hospital in Prague (RVO-VFN64165). The recruitment of the Russian cohort was supported by the Government Assignment of the Russian Ministry of Health, Assignment 200080056 of the Veltischev Research and Clinical Institute for Pediatrics of the Pirogov Russian National Research Medical University. The recruitment of the Swedish cohort was supported by the Nephrology and Rheumatology Departments at Karolinska University Hospital and Karolinska Institutet, Stockholm, and grants from the Swedish Society of Medicine. We thank the Immunopathology Working Group of the Italian Society of Nephrology (ISN) for inviting their member sites to contribute to this study. We are also grateful to the Pediatric Nephrology Research Consortium (PNRC) for hosting and cosponsoring the GIGA-kids study that recruited pediatric patients with IgAN across the PNRC sites. We are additionally grateful to C. Bowers for coordinating GIGA-kids and PMRC-based recruitment, J. Narus for coordinating recruitment at the University of Utah, E. Elenberg and S. Shah for helping enroll participants from Texas Children’s Hospital and A. Suwanichkul for sample shipping. The recruitment of the Korean cohort was supported by the Seoul National University Hospital Human Biobank, a member of the National Biobank of Korea, financed by the Ministry of Health and Welfare, Republic of Korea. We are grateful to the International Multiple Sclerosis Genetics Consortium (IMSGC), the Inflammatory Bowel Disease Genetics Consortium (IBDGC), the International Myositis Consortium (IMC), the Feinstein Institute for Medical Research, the French Biological Ressource Center for MS Genetics (REFGENSEP), Genethon and INSERM for contributing Immunochip controls for the purpose of this study. We also thank the Population Architecture Using Genomics and Epidemiology (PAGE) consortium, funded by the NHGRI with cofunding from the NIMHD, for providing population controls genotyped with MEGA chip for this study. Molecular graphics shown in Extended Data Fig. were generated using UCSF Chimera, developed by the Resource for Biocomputing, Visualization and Informatics at the University of California, San Francisco, with support from NIH P41-GM103311. The funding sources were not involved in the study design, collection, analysis and interpretation of data, writing of the report or the decision to submit the paper for publication.

Funding Information:
B.A.J. and J. Novak are cofounders, co-owners of, and consultants for Reliant Glycosciences, LLC, and are co-inventors on US patent application 14/318,082 (assigned to UAB Research Foundation). A.G.G. has served on an advisory board for Novartis, Travere and Natera and receives research grant funding from the Renal Research Institute and Natera. K.K. has served on an advisory board for Goldfinch Bio and Gilead. The other authors report no competing interests.

Publisher Copyright:
© 2023, The Author(s), under exclusive licence to Springer Nature America, Inc.